Products

Study Watch with Irregular Pulse Monitor (Home)
Verily Life Sciences LLC
Cardiology AI
The Verily Study Watch with Irregular Pulse Monitor (Home) is a prescription-only wearable device for clinical research and healthcare use, designed to unobtrusively collect physiological data, including ECG and irregular pulse monitoring, with advanced sensors and cloud-based analytics.
Study Watch
Verily Life Sciences
Cardiology AI
Verily Study Watch is a prescription-only, sensor-based wearable device for non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis in Verily's cloud platform.
Study Watch with Irregular Pulse Monitor
Verily Life Sciences
Cardiology AI
The Verily Study Watch with Irregular Pulse Monitor is an FDA-cleared, prescription-only wearable device from Verily Life Sciences. It is designed for adult patients (22+) to monitor and record single-channel ECG rhythms and detect irregular pulses indicative of atrial fibrillation, primarily for use in clinical research and professional healthcare settings.

See all 3 products →

About Verily Life Sciences

Verily Life Sciences, an Alphabet company that recently transitioned to an independent entity with Alphabet as a significant minority investor, operates at the intersection of technology, data science, and healthcare. Its core mission is to leverage health data to enable healthier lives by developing advanced tools, platforms, and solutions for collecting, organizing, analyzing, and activating health information. For physicians, Verily aims to deliver AI-enabled precision health solutions designed to accelerate research and enhance patient care, ultimately making healthcare more personalized, predictive, and precise. The company fosters an interdisciplinary approach, combining expertise in science, engineering, and medicine with a startup ethos, and collaborates extensively with partners across the healthcare and life sciences industries.

Verily’s offerings include the Verily Pre platform, which is engineered to assist life sciences companies and researchers in organizing fragmented healthcare records, genomic datasets, and data from wearables. This platform facilitates AI-driven analysis, biomarker discovery, and the acceleration of clinical trials. Additionally, Verily develops technology-based interventions such as Lightpath, an AI-native care management platform specifically for chronic conditions like diabetes, obesity, and hypertension. The company’s portfolio also encompasses major projects like Project Baseline Health studies, molecular diagnostics, and population health analytics, all utilizing advanced analytics, software, and devices to build comprehensive precision health technologies. Verily has also expanded its services to include wastewater testing and has received awards for its data and technology consortiums.

Focus Areas

Precision health AI-driven healthcare solutions Clinical research Advanced healthcare analytics Chronic disease management Real-world evidence generation Data harmonization AI model development Digital precision medicine Public health pathogen tracking

Business Intelligence

Key InvestorsAlphabet, Series X Capital, UCHealth, University of Colorado Anschutz, Temasek Holdings, Silver Lake, Ontario Teachers' Pension Plan, Swiss Re Corporate Solutions
PartnershipsSamsung (Galaxy Watch 8 integration), Salesforce (Agentforce Health integration), NVIDIA (AI tech stack integration), UCHealth, University of Colorado Anschutz, RefinedScience (AI-powered research and care transformation), Bangor University (wastewater testing in Europe), National Institutes of Health (data and technology consortium award), OneOncology (cancer research), Lumea (digital pathology and AI-enabled tools), HealthVerity (clinical trial landscape)
AcquisitionsLift Labs (2014), SignalPath (2021)
TechnologyAI-native platform, Verily Pre platform, Refinery (health data harmonization), Exchange, Workbench (multi-modal data analysis, secure analytics environment), Baseline platform (clinical trial system and evidence generation), Verily Intelligence
FDA Clearances4 cleared products (estimated)

What Physicians Need to Know

Precision Health Platform
Verily's core offering, the Pre platform, is purpose-built for AI-enabled precision health, empowering researchers and innovators to harmonize, exchange, govern, and analyze biomedical data to deliver personalized, predictive, and precise healthcare solutions.
AI-Driven Healthcare Solutions
Verily integrates NVIDIA's AI technology stack, including NVIDIA NeMo, NVIDIA Parabricks, and NVIDIA CUDA-X Data Science, into its Pre platform to dramatically speed up complex tasks like analyzing patient genomic data and developing advanced AI models for disease prediction and proactive health management.
Clinical Research Acceleration
Through solutions like Viewpoint Evidence and the Pre platform's Refinery, Exchange, and Workbench, Verily helps life sciences partners solve data challenges with research-ready datasets and secure analytics environments. This accelerates clinical development by enabling more relevant trial designs, efficient participant follow-up, and robust real-world evidence generation.
Advanced Healthcare Analytics
The Pre platform provides an end-to-end ecosystem for the data value chain, from data discovery and enrichment to analysis and AI development. It leverages GPU-accelerated libraries to transform raw data into actionable insights, significantly reducing analysis time for complex datasets.
Real-World Evidence Generation
Viewpoint Evidence generates unified, longitudinal views of participant health journeys by connecting records across health systems, pharmacies, and personal devices, and directly engaging individuals for research that reflects real life. This is further enhanced by integrating consumer wearable data, such as from Samsung Galaxy Watch.
Data Harmonization & Interoperability
The Refinery solution within the Pre platform ingests, unifies, and pre-processes disparate multimodal data through curation and enrichment, creating comprehensive, clinically labeled, and standardized datasets. It standardizes data to the FHIR-native data model, ensuring quality and interoperability.
AI Model Development
Verily accelerates the development of AI agents and models, including the creation of multimodal foundation models using extensive datasets like the NIH All of Us Research Program, by integrating EHR and genomics data for more holistic health profiles.
Digital Precision Medicine
Verily's overarching mission is to bridge the gap between research and care through innovative health technology, leveraging AI, data science, and multidisciplinary expertise to enable more personalized, predictive, and precise healthcare.
Physician Tip

For physicians, Verily Life Sciences offers tools that can significantly enhance patient care and clinical research. Their AI-driven Pre platform accelerates the analysis of complex patient data, including genomics, leading to faster insights for diagnosis and treatment decisions. Physicians can benefit from enhanced clinical research capabilities, allowing for the design of more relevant trials, efficient patient engagement, and the capture of real-world outcomes. The integration of multimodal data, including wearable sensor streams, supports the creation of more holistic patient profiles, enabling truly personalized care and proactive health management. Furthermore, Verily's focus on data harmonization ensures access to high-quality, standardized datasets, which can inform clinical decision-making and support the generation of robust real-world evidence.

Verily's Pre Platform is designed for extensive integration, serving as a central hub for various healthcare data sources and technologies. Key integrations include NVIDIA's AI technology stack for accelerated computing and AI model development, Samsung Galaxy Watch for real-world wearable data collection in clinical studies, and Salesforce Health for powering enterprise precision health solutions. The platform's emphasis on data harmonization and FHIR-native data models facilitates interoperability across diverse systems and datasets.

Products by Verily Life Sciences

3 products in the directory

Study Watch with Irregular Pulse Monitor (Home)
Verily Life Sciences LLC
Cardiology AI
The Verily Study Watch with Irregular Pulse Monitor (Home) is a prescription-only wearable device for clinical research and healthcare use, designed to unobtrusively collect physiological data, including ECG and irregular pulse monitoring, with advanced sensors and cloud-based analytics.
Study Watch
Verily Life Sciences
Cardiology AI
Verily Study Watch is a prescription-only, sensor-based wearable device for non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis in Verily's cloud platform.
Study Watch with Irregular Pulse Monitor
Verily Life Sciences
Cardiology AI
The Verily Study Watch with Irregular Pulse Monitor is an FDA-cleared, prescription-only wearable device from Verily Life Sciences. It is designed for adult patients (22+) to monitor and record single-channel ECG rhythms and detect irregular pulses indicative of atrial fibrillation, primarily for use in clinical research and professional healthcare settings.

What the Web Says

Verily Life Sciences, an Alphabet Inc. subsidiary, focuses on precision health solutions by integrating healthcare, technology, and data sciences. The company aims to improve health outcomes through various platforms and products, including AI-driven tools for research, care delivery, and public health initiatives. While employees often praise the challenging and innovative work environment, there are recurring concerns about management, long-term strategy, and job security.

Overall: Mixed

Strengths

  • Innovative and impactful mission in healthcare.
  • Smart, supportive, and collaborative colleagues.
  • Competitive compensation and benefits, especially for engineering roles.
  • Good work-life balance and flexible work schedules.
  • Opportunities for learning new skills and professional development.
  • Strong Alphabet funding provides a good chance for success.

Limitations

  • Incompetent management and lack of clear long-term strategy.
  • Issues with job security and advancement, including unfulfilled promises for full-time conversion.
  • Frequent shifts in company leadership and project goals.
  • Unprofessional leadership in recruiting.
  • Workload can spike unpredictably due to a startup mindset within a large company.
  • Some former employees express skepticism about the company's actual offerings and impact.

Based on reviews from: Indeed.com, Nebula Genomics, Comparably, Quora, Reddit, Grokipedia, Forbes, Fierce Healthcare, G2

Last updated: 2026-07-19

Videos

News, demos, and interviews about Verily Life Sciences.

Loading videos...

Videos load interactively. If none appear, search YouTube for Verily Life Sciences →

View all on YouTube

Press & Coverage

SiliconANGLE
Verily steps out from under Alphabet's shadow after raising $300M to advance precision health
Verily Life Sciences raised $300 million in funding, led by Series X Capital, and is restructuring to become an independent entity focused on AI-driven precision health, officially changing its name to Verily Health Inc.. Alphabet will remain a significant minority investor, but no longer holds a controlling stake, which is expected to enhance Verily's ability to integrate its technology within the healthcare industry.
2026-03
Fierce Healthcare
Verily banks $300M to fuel AI road map, separates from Alphabet
Verily secured $300 million in investment to advance its AI and precision health initiatives, transitioning from an LLC to a corporation named Verily Health.. This funding will support the expansion of its Verily Pre and Verily Me platforms, the launch of new AI agents, and global commercial opportunities.
2026-03
Verily Press Release
Verily Health Provides Wastewater Monitoring and Data Analytics to Safeguard Public Health During the 2026 World Soccer Games
Verily Health announced it will provide wastewater monitoring and data analytics to help safeguard public health during the 2026 World Soccer Games.. This initiative highlights Verily's involvement in public health solutions, including its Sightline wastewater-based epidemiology program.
2026-05
Onyx Newsroom
Verily launches free version of its Pre Exchange and Workbench solutions, powering precision health AI and discovery
Verily launched self-serve access to its Pre precision health platform, introducing a free Standard tier for individual researchers to access Exchange and Workbench solutions.. This aims to lower the barrier for discovering and analyzing diverse biomedical datasets within a secure research environment.
2026-02
Verily Press Release
Verily-led consortium secures $9.2M NIH award extension for platform to advance systems biology research
A Verily-led consortium received a $9.2 million NIH award extension for the FAIRplex Platform, which will facilitate data analysis across Accelerating Medicines Partnershipu00ae programs.. This platform aims to unlock new discoveries about human health and disease through systems biology research.
2025-12
Verily Press Release
Verily Launches a New Consumer Health App, Verily Me, at HLTH USA 2025
Verily launched Verily Me, a new consumer health app designed to close gaps in care and keep individuals engaged in their health journey.. The app offers personalized recommendations from licensed clinicians and is used by members of Verily's Lightpath personalized care program.
2025-10
PYMNTS.com
Alphabet Prepares to Sell Life Sciences Unit Verily
Alphabet has been preparing for two years to sell its life sciences unit, Verily, according to a company executive.. This news comes as Verily has been divesting business units and sharpening its focus on its AI healthcare platform, Pre.
2025-10
Medical Device and Diagnostic Industry
Medtech in a Minute: A Verily Big Decision & More
Verily, Alphabet's life sciences company, has reduced its workforce and discontinued its medical device program to concentrate on data and AI.. This strategic shift aligns with Verily's focus on its AI healthcare platform, Pre.
2025-08

Frequently Asked Questions

Verily's core mission is to make health data useful to enable healthier lives through precision health, leveraging AI to transform complex health data into actionable insights. Their AI-native Pre platform harmonizes diverse data for advanced analytics and AI deployment, while the Verily Me app offers personalized health recommendations and AI assistance for individuals.
Verily accelerates clinical research and real-world evidence generation through its Viewpoint Evidence solution, which leverages the Pre platform to unify longitudinal health data from various sources and engage participants in ongoing studies like the Lifelong Health Study. This approach, supported by partnerships with life sciences organizations, aims to streamline trials and provide richer, more dynamic insights into patient journeys.
Verily addresses chronic disease management with solutions like Lightpath, an AI-powered personalized chronic care program, initially focusing on cardiometabolic conditions such as diabetes and hypertension. Lightpath leverages AI to create tailored care plans, integrate data from health records and devices, and offer continuous support to members.
Verily's Pre platform, including Refinery and Workbench, is purpose-built to harmonize diverse, multimodal health data into a standardized, AI-ready format, often FHIR-native. This platform supports advanced analytics and AI model development, with collaborations like NVIDIA enhancing capabilities for creating AI agents and models for research and care.
Verily contributes to public health through its Sightline wastewater program, which employs wastewater-based epidemiology to track the spread of various viral and fungal pathogens in communities. This provides near real-time data, enabling public health officials to make informed decisions for early detection, prevention, and resource distribution.
Verily prioritizes data privacy and security, adhering to standards like HIPAA, SOC 2 Type II, and ISO/IEC 27001 across its platforms. They employ security by design principles, including strong encryption and restricted access, though the company has faced a lawsuit alleging past HIPAA violations, which it is addressing.
Verily recently secured $300 million in funding and transitioned to an independent entity, Verily Health Inc., with Alphabet as a significant minority investor, aiming to bolster its precision health AI strategy and market neutrality. They maintain extensive partnerships with healthcare systems like UCHealth, tech giants such as Samsung, Salesforce, and NVIDIA, and pharmaceutical companies to advance research and care solutions.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.